High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.
about
Future perspectives in target-specific immunotherapies of myasthenia gravisRapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodiesHow pre-existing, germline-derived antibodies and complement may help induce a primary immune response to nonself.Outcome of severe encephalomyelitis in children: effect of high-dose methylprednisolone and immunoglobulins.Cutaneous dermatomyositis: an updated review of treatment options and internal associations.Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients.Treatment of Clinically Amyopathic Dermatomyositis in adults: A Systematic Review.Intravenous immunoglobulin in neurological disease: a specialist review.Immunoglobulin isotype isolated from human placental extract does not interfere in complement-mediated bacterial opsonization within the wound milieu.Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseasesThe composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy.IVIG in APS pregnancy.Efficacy of Intravenous Immunoglobulin in Neurological Diseases.Treatment of inflammatory myopathies.Targeting ischemic brain injury with intravenous immunoglobulin.IVIg attenuates complement and improves spinal cord injury outcomes in mice.Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.Terminal complement activation is increased and associated with disease severity in CIDPVascular involvement in the pathogenesis of idiopathic inflammatory myopathies.Intravenous immunoglobulins--understanding properties and mechanisms.Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science.Review: An update on inflammatory and autoimmune myopathies.Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease.Intravenous immunoglobulin therapy in rheumatic diseases.Platelets in inflammation and immune modulations: functions beyond hemostasis.Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future.Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies.Subcutaneous IgG in neurologic diseases.The expanding role of therapeutic antibodies.Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations.Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all?Intravenous immunoglobulin in the treatment of neurologic disorders.IVIG-mediated effector functions in autoimmune and inflammatory diseases.Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases.Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes.Modulation of autoimmune responses by intravenous immunoglobulin (IVIg).Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?Neutralization of disease associated autoantibodies by an immunoglobulin M- and immunoglobulin A-enriched human intravenous immunoglobulin preparation.
P2860
Q26776225-E5F58A83-E938-4E5E-BEEF-1EC3892AC494Q26864907-7892644E-4DAC-4186-9ED3-E3F0242203ADQ33548139-DB8F2983-0A2E-4120-9F84-18C3B606EB57Q33964341-F8FF7E27-42FA-4C08-91F4-7ECA5E6E92BAQ34349952-DBFF4C23-B83C-4A0C-99E0-FDE4F0C089E0Q34521023-1E0884D1-C9D0-42EA-938D-987B49BE4A03Q34526090-D1855BD4-82C9-4CCC-849F-1EC9732B0D30Q34574581-6094F3C6-A656-47A0-B11F-CB28A46BA199Q35605456-6CA63A05-0AAD-4188-9089-B38BB6FA4AF7Q35753525-72248819-9244-4CC2-971C-325C68848AA1Q35876136-B77F6BEC-4FF9-42B2-A2F3-F261D8206203Q35918396-BC2798BA-10CE-40FE-A966-1BC43DE8B8E7Q36484438-481560B6-1F1D-4061-992C-402E9AB53331Q36528220-3D23E3FB-E43E-427A-BC39-36B62F63FB4BQ37030865-881AB396-3D2F-4F33-BD45-11BC8E753EE8Q37062115-D32E1765-0F8C-4AB9-9677-487AA624B2EDQ37091310-AEC80A76-441F-44EF-9060-703681511918Q37247076-15D46B57-ED29-424F-AF19-6330476C5691Q37622947-A8B657FB-A0D0-4ED6-9BBF-B9EA21019435Q37626118-B2B58DED-9112-4F90-9AE2-E7CC6F321F49Q37773248-88569F13-731E-4B6A-8E0D-7A587A977578Q37820692-0F90A98F-14DD-4A15-BB34-BE1F22F63128Q37866685-DB6FBFCE-C594-4D0D-89BD-B81764287154Q37873722-FE583A20-3EB9-468E-9809-C35FC9A22F60Q38039852-3181B6E3-7EC3-41AA-BA1A-DACF75F91784Q38068530-EE453A45-8F40-40F7-87EB-C82F79BFA16DQ38089081-BA4F564D-8533-47C9-A3DF-3AB079367208Q38171572-3B85B90F-6C05-4460-80AB-EF6A5E977059Q38182645-4F7DADEC-8C1B-4761-B11C-E313B714AC42Q38203801-53D3BE42-43F5-44BF-90C7-B4B50EA460B1Q38283308-13217594-C8E2-4E69-99E1-0ED19A990D2CQ38308436-1FADABAC-16F9-40A7-9894-A45702ACCF00Q38344833-25D3DC5A-3EA3-43EE-98AC-574273E6A6E5Q38495457-9C1EBEC2-9BEA-489B-BEC3-5A792A167F50Q38699812-82A56A15-40B1-4998-A35A-BB2A96B6094DQ39090725-CBBDA171-6A10-46B0-AC1B-4181BB795517Q39579621-FA514B39-5CF4-46C1-8890-F97C93F729DBQ41589724-2D5DA906-4B47-4FC7-A984-23310180F428Q42375731-1F6914A6-36AE-41BD-ACEA-BC34AD95083DQ45276421-D5BA5669-3431-49D2-AD9E-07641601EF1D
P2860
High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.
description
1994 nî lūn-bûn
@nan
1994 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
High-dose intravenous immunogl ...... ctivated complement fragments.
@ast
High-dose intravenous immunogl ...... ctivated complement fragments.
@en
High-dose intravenous immunogl ...... ctivated complement fragments.
@nl
type
label
High-dose intravenous immunogl ...... ctivated complement fragments.
@ast
High-dose intravenous immunogl ...... ctivated complement fragments.
@en
High-dose intravenous immunogl ...... ctivated complement fragments.
@nl
prefLabel
High-dose intravenous immunogl ...... ctivated complement fragments.
@ast
High-dose intravenous immunogl ...... ctivated complement fragments.
@en
High-dose intravenous immunogl ...... ctivated complement fragments.
@nl
P2860
P921
P356
P1476
High-dose intravenous immunogl ...... ctivated complement fragments.
@en
P2093
P2860
P304
P356
10.1172/JCI117520
P407
P577
1994-11-01T00:00:00Z